Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Concept Videos

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents01:29

Drugs for Treatment of Crohn's Disease in IBD Using Immunomodulatory Agents

170
Crohn's disease is an inflammatory bowel disorder marked by chronic inflammation of the GI tract. Various treatment strategies for Crohn's disease are employed, such as immunomodulatory agents, glucocorticoids, and biologics or anti-TNF therapy. Azathioprine (Imuran), a commonly used immunomodulatory drug for Crohn's disease, is converted in the body to mercaptopurine, which inhibits purine biosynthesis and cell proliferation. Both are utilized in severe cases of Inflammatory Bowel...
170

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

Epidemiological Trends of Vascular Intestinal Disease in the Elderly (1990-2021): A Study on Its Causal Relationship With Hypertension.

Journal of digestive diseases·2026
Same author

Microbial Anti-Inflammatory Molecule (MAM) secreted by Faecalibacterium prausnitzii ameliorates colitis through autophagy and gut microbiota modulation.

Journal of translational medicine·2025
Same author

Mast cell-derived exosomes and claudin regulation in ulcerative colitis: emerging insights and therapeutic potential.

Nanoscale advances·2025
Same author

Secondary Bile Acids Modified by Odoribacter Splanchnicus Alleviate Colitis by Suppressing Neutrophil Extracellular Trap Formation.

Advanced science (Weinheim, Baden-Wurttemberg, Germany)·2025
Same author

Identification of Glycolysis-Related Genes in MAFLD and Their Immune Infiltration Implications: A Multi-Omics Analysis with Experimental Validation.

Biomedicines·2025
Same author

Odoribacter splanchnicus-A Next-Generation Probiotic Candidate.

Microorganisms·2025

Related Experiment Video

Updated: Jul 12, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

854

Rapamycin extenuates experimental colitis by modulating the gut microbiota.

Xue Guo1,2, Jing Xu1,2, Chen Huang2

  • 1Department of Gastroenterology and Hepatology, School of Medicine, The Second Affiliated Hospital, South China University of Technology, Guangzhou, China.

Journal of Gastroenterology and Hepatology
|November 2, 2023
PubMed
Summary

Rapamycin treatment improved experimental colitis in mice by modulating the gut microbiota. Autophagy activation

Keywords:
IBDautophagygut microbiotarapamycin

More Related Videos

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.2K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Related Experiment Videos

Last Updated: Jul 12, 2025

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation
08:53

Investigating the Alleviating Effects of Bacillus cereus Administration on Colitis through Gut Microbiota Modulation

Published on: July 27, 2022

854
Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin
10:21

Mechanistic Insight into the Development of TNBS-Mediated Intestinal Fibrosis and Evaluating the Inhibitory Effects of Rapamycin

Published on: September 12, 2019

7.2K
Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model
05:41

Therapeutic Evaluation of Fecal Microbiota Transplantation in an Interleukin 10-Deficient Mouse Model

Published on: April 6, 2022

2.9K

Area of Science:

  • Gastroenterology
  • Microbiology
  • Immunology

Background:

  • Inflammatory bowel disease (IBD) pathogenesis involves complex interactions between autophagy and the gut microbiota.
  • Dysbiosis and altered autophagy are key features of IBD, suggesting potential therapeutic targets.

Purpose of the Study:

  • To investigate the therapeutic effects of rapamycin on experimental colitis.
  • To elucidate the role of gut microbiota modulation in rapamycin's efficacy for inflammatory bowel disease.

Main Methods:

  • Acute colitis was induced in mice using dextran sodium sulfate (DSS) and trinitrobenzenesulfonic acid.
  • Mice were treated with rapamycin or hydroxychloroquine, and outcomes were assessed via clinical scores, histology, cytokine levels, and intestinal permeability.
  • Gut microbiota composition was analyzed using 16S rRNA sequencing, and the role of the microbiome was further explored using antibiotic-induced depletion.

Main Results:

  • Rapamycin treatment ameliorated colitis, reducing disease activity, improving colon length, and decreasing inflammatory markers (IL-6, TNF-α).
  • Rapamycin intervention altered gut microbiota composition, increasing the abundance of beneficial bacteria like Lactobacillus and Mucispirillum.
  • The therapeutic benefits of autophagy activation were diminished following gut microbiome depletion, highlighting the microbiome's critical role.

Conclusions:

  • Rapamycin demonstrates therapeutic potential in experimental colitis, likely mediated through its influence on the gut microbiota.
  • Targeting the gut microbiota in conjunction with autophagy modulation may represent a novel therapeutic strategy for inflammatory bowel disease.